Interpretation of the Chinese Clinical Practice Guideline on the Management of Crohn's Disease(2023,Guangzhou)
The Inflammatory Bowel Disease Group of the Gastroenterology Branch of the Chinese Medical Association formulated and issued the Chinese Clinical Practice Guideline on the Management of Crohns Disease(2023,Guangzhou).This guideline has been revised and updated on the basis of the Chinese Consensus on Diagno-sis and Treatment in Infllammatory Bowel Disease(2018,Beijing).Through the engagement of an evidence-based team and a strict formulation process,the guideline covers the diagnostic methods,therapeutic regime,perioperative management,treatment of perianal lesions and disease surveillance of Crohn's disease,with an aim of standardizing the diagnosis and treatment of Crohn's disease.In comparison with the 2018 Consensus,the main updated contents included:reconfirmation of diagnostic criteria and high-risk factors,the application of non-inva-sive methods,the notion of"treat-to-target",selection of multiple biological agents and small molecule drugs,more aggressive management for anal fistula,as well as the importance of perioperative management.Through literature research,the present review interprets the abovementioned updates by comparing the recommendations in the 2023 Guideline with the previous consensus,and finally explores its application in clinical practice.
NETL
NSTL
万方数据
